SPINOZA Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma.

Trial Profile

SPINOZA Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms SPINOZA
  • Most Recent Events

    • 02 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2012 Lead trial centres added as reported by ClinicalTrials.gov.
    • 03 Dec 2012 Planned number of patients changed from 100 to 158 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top